Japanese company blames laser tool for its 2nd crash landing on the moon
Officials for ispace announced the news from Tokyo on Tuesday. The crash landing was the second for ispace in two years.
This time, the company's lander named Resilience was aiming for the moon's far north in Mare Frigoris, or Sea of Cold. NASA's Lunar Reconnaissance Orbiter relayed pictures of the crash site last week where Resilience and its mini rover ended up as wreckage.
Company officials blamed the accident on the lander's laser range finder, saying it did not properly measure the spacecraft's distance to the lunar surface. Resilience was descending at a rapid rate of 138 feet (42 meters) per second when contact was lost, and crashed within seconds, they said.
Bad software caused ispace's first lunar lander to slam into the moon in 2023. Like the latest try, the problem occurred during the final phase of descent.
Of seven moon landing attempts by private outfits in recent years, only one can claim total success: Firefly Aerospace's touchdown of its Blue Ghost lander in March. Blue Ghost launched with Resilience in January, sharing a SpaceX rocket ride from Florida.
Aside from Texas-based Firefly, only five countries have pulled off a successful lunar landing: the Soviet Union, the U.S., China, India and Japan. And only the U.S. has put astronauts on the moon, back during NASA's Apollo program more than a half-century ago.
Despite back-to-back losses, ispace is pressing ahead with its third moon landing attempt in 2027, with NASA cooperation, as well as a fourth planned mission.
CEO and founder Takeshi Hakamada stressed that his company 'has not stepped down in the face of setbacks" and is looking to regain customers' trust. 'We're firmly taking the next step toward our future missions,' he said in Japanese.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
39 minutes ago
- Associated Press
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Olympus Co-founds Swan EndoSurgical With Revival Healthcare Capital TOKYO - July 28, 2025 ( NEWMEDIAWIRE ) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future. Endoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment options that support safety and improved recovery times. This groundbreaking advancement has the potential to create new and significantly enhanced minimally invasive treatment options for major unmet medical needs by boosting precision and efficiency in procedures addressing ergonomic strain for healthcare professionals. Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, commented, 'This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics. We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians. This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.' For decades, endoscopy - placing a flexible camera into an existing body orifice - has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally. The development of an endoluminal robot, with its ability to easily maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas. Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of highly experienced industry professionals who will drive technical, clinical, and commercial development of the robotic platform. About Swan EndoSurgical Swan EndoSurgical, Inc. is an innovative start-up co-founded by Revival Healthcare Capital and Olympus that is focused on the development of endoluminal surgical robotics with the aim to create effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. For additional information, visit the Company's website at or contact [email protected]. About Revival Healthcare Capital Revival Healthcare Capital is an investment firm focused on the MedTech sector. Revival specializes in transformative external innovation partnerships and other opportunities where its team of experienced operators and investors believes it can provide leadership, resources, and deep sector insights - beyond its capital - to further support companies' growth strategies. For additional information, visit Revival's website at or contact [email protected] . About Olympus At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit and follow our global X account: @Olympus_Corp. Media contact: Mail: [email protected] Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS]
Digital Trends
an hour ago
- Digital Trends
Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video
NASA's incredible Ingenuity helicopter spent nearly three flying across the surface of Mars, becoming the first aircraft to achieve powered, controlled flight on a planet other than Earth. After suffering damage to one of its blades in early 2024, Ingenuity was grounded for good, and now rests on the martian surface as a testament to technological innovation and the triumph of autonomous flight on another planet. In an exciting development, the plucky helicopter has now inspired Skyfall, a mission concept recently unveiled by Virginia-based AeroVironment (AV) and NASA's Jet Propulsion Laboratory (JPL), who worked together to develop the Ingenuity aircraft. As you can see in the video at the top of this page, the Skyfall mission is designed to deploy not one but six helicopters on Mars, each of which would fly off to explore various locations selected by NASA as potential landing spots for the first crewed mission to the red planet, which could take place in the 2030s. The gathered data could also help scientists learn more about Mars, contributing to the expanding database of information collected by other Mars vehicles such as the Perseverance and Curiosity rovers. The video shows the dramatic Skyfall Maneuver, described by AV as 'an innovative entry, descent, and landing technique whereby the six rotorcraft deploy from their entry capsule during its descent through the martian atmosphere.' With the helicopters flying down to the Mars surface under their own power, the Skyfall system would do away with the need for a landing platform, which is one of the most expensive parts of any Mars mission and also carries huge risk. Just like Ingenuity, each helicopter would be capable of operating autonomously, and beam high-resolution imagery back to Earth for analysis, allowing mission planners to select the best possible landing location for the first human mission. 'Skyfall offers a revolutionary new approach to Mars exploration that is faster and more affordable than anything that's come before it,' said William Pomerantz, head of space ventures at AV. 'Thanks to a true partnership between industry and government, we're expanding the unprecedented success of Ingenuity.' Pomerantz added that with six helicopters, 'Skyfall offers a low-cost solution that multiplies the range we would cover, the data we would collect, and the scientific research we would conduct, making humanity's first footprints on Mars meaningfully closer.' With NASA's first human missions in mind and the need to identify an ideal landing area, AV is already working with NASA's JPL in the hope of getting the green light for the mission before working toward a potential 2028 launch.
Yahoo
2 hours ago
- Yahoo
Undiscovered Asian Gems with Strong Potential In July 2025
As global markets reach new heights, buoyed by favorable trade deals and robust economic indicators, the Asian markets are also experiencing a wave of optimism. With recent developments in trade agreements and economic resilience, investors are increasingly looking towards small-cap stocks in Asia for their potential to capitalize on these dynamic conditions. In this environment, identifying promising companies involves assessing their ability to adapt to changing market landscapes while leveraging regional growth opportunities. Top 10 Undiscovered Gems With Strong Fundamentals In Asia Name Debt To Equity Revenue Growth Earnings Growth Health Rating AIC NA 26.88% 54.47% ★★★★★★ Toho 72.03% 6.01% 64.19% ★★★★★★ PSC 15.34% 1.17% 10.86% ★★★★★★ Nantong Guosheng Intelligence Technology Group NA 8.02% 1.71% ★★★★★★ HeXun Biosciences NA 74.95% 119.41% ★★★★★★ Zhejiang JW Precision MachineryLtd 12.36% 4.29% -22.66% ★★★★★★ Wholetech System Hitech 3.31% 15.16% 19.61% ★★★★★☆ Zhejiang Jinghua Laser TechnologyLtd 2.85% 4.02% -2.43% ★★★★★☆ Ningbo Henghe Precision IndustryLtd 66.02% 5.50% 23.91% ★★★★☆☆ Keli Motor Group 35.39% 9.99% -14.86% ★★★★☆☆ Click here to see the full list of 2601 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Quechen Silicon Chemical Simply Wall St Value Rating: ★★★★★★ Overview: Quechen Silicon Chemical Co., Ltd. operates in the manufacture and supply of silica both in China and internationally, with a market capitalization of CN¥8.11 billion. Operations: Quechen Silicon Chemical generates revenue primarily from its Specialty Chemicals segment, amounting to CN¥2.21 billion. Quechen Silicon Chemical, a nimble player in the chemicals sector, has shown robust growth with earnings surging 23.4% over the past year, outpacing the industry's modest 4% rise. The firm is trading at a compelling value, sitting 33.4% below its estimated fair value. It boasts high-quality earnings and maintains an impressive debt-to-equity ratio that has shrunk from 9% to just 2.3% over five years. With strong free cash flow and profitability ensuring no worries about cash runway, Quechen appears well-positioned for continued growth with forecasts suggesting an annual earnings increase of nearly 11.82%. Click here and access our complete health analysis report to understand the dynamics of Quechen Silicon Chemical. Understand Quechen Silicon Chemical's track record by examining our Past report. HangzhouS MedTech Simply Wall St Value Rating: ★★★★★★ Overview: Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China with a market cap of approximately CN¥6.65 billion. Operations: HangzhouS MedTech generates revenue primarily from the sale of endoscopic surgery equipment and accessories. The company's net profit margin has shown a notable trend, reflecting its financial health and efficiency in managing costs relative to its revenue streams. With no debt over the past five years, HangzhouS MedTech showcases financial prudence, underscored by high-quality earnings. The company's earnings growth of 25.9% in the last year significantly outpaced the Medical Equipment industry average of -2.2%. Trading at a value 24.8% below its estimated fair value, it offers an attractive proposition compared to peers and industry standards. Levered free cash flow has shown a steady rise, reaching US$267.89 million recently, hinting at robust operational efficiency despite capital expenditures of US$41.16 million in the same period. Future growth prospects appear promising with forecasted annual earnings growth of 20.76%. Dive into the specifics of HangzhouS MedTech here with our thorough health report. Explore historical data to track HangzhouS MedTech's performance over time in our Past section. Medprin Regenerative Medical Technologies Simply Wall St Value Rating: ★★★★★★ Overview: Medprin Regenerative Medical Technologies Co., Ltd. is a company specializing in the development and manufacture of innovative regenerative medical products, with a market cap of CN¥4.96 billion. Operations: Medprin Regenerative Medical Technologies generates revenue through the development and manufacture of regenerative medical products. The company's financial performance is highlighted by a notable net profit margin, reflecting its efficiency in managing costs relative to its revenue streams. Medprin Regenerative Medical Technologies, a nimble player in the medical equipment sector, showcases impressive financial health with no debt and an earnings growth of 83.5% over the past year, outpacing the industry average of -2.2%. The company has transitioned to positive levered free cash flow recently, reaching CNY 102.39 million by mid-2025 from negative figures in prior years. Despite recent share price volatility, Medprin's strategic moves include a private placement at CNY 48.03 per share to raise funds for asset purchases and operational support, reflecting robust shareholder confidence and positioning it well for future endeavors. Delve into the full analysis health report here for a deeper understanding of Medprin Regenerative Medical Technologies. Gain insights into Medprin Regenerative Medical Technologies' past trends and performance with our Past report. Taking Advantage Take a closer look at our Asian Undiscovered Gems With Strong Fundamentals list of 2601 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:605183 SHSE:688581 and SZSE:301033. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
